Industry News Headlines April 15, 2004 - May 14, 2004

June 2004
PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20
Market Research Report
Reports developments in the biotechnology industry as of April 2004. Acquisition of Shire Pharmaceuticals by ID Biomedical Corp.; Details on the lawsuit filed by Biota against GlaxoSmithKline PLC for failure to promote influenza drug; Sale of Zonegran, an ani-epiletic drug to Eisai Inc.


Related Articles

  • ID Biomedical to acquire Shire Pharmaceuticals vaccine business.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20 

    Reports on the acquisition of the vaccine business of Shire Pharmaceuticals by ID Biomedical Corp. Total amount of the deal; Services of ID; Details on the marketing of vaccines.

  • Shire to acquire Jerini.  // PharmaWatch: Biotechnology;Aug2008, Vol. 7 Issue 8, p16 

    The article reports on the strategic agreement reached by Jerini AG and Shire PLC. It claims that Shire will make a voluntary public takeover offer to all shareholders of Jerini. It will also be offering E6.25 per share in cash for all shares issued by Jerini which can be totalled to E328...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/23/2007, Vol. 18 Issue 78, p2 

    The article offers news briefs on the biotechnology industry worldwide. Addex Pharmaceuticals SA of Geneva, Switzerland has completed its Phase IIa trial of its ADX10059 in patients with migraine. AVI BioPharma Inc. of Portland, Oregon has purchased a building in Corvallis, Oregon. Shire plc of...

  • Chiron's manufacturing misfortunes boost competitors. Sheridan, Cormac // Nature Biotechnology;Oct2005, Vol. 23 Issue 10, p1191 

    The article focuses on problems faced by Chiron Corp., the world's second largest flu vaccine supplier. Chiron's ongoing problems in influenza vaccine production have raised serious questions about the Emeryville, California company's future ability to compete in this particular segment of the...

  • GSK catches flu shot.  // Chemical Market Reporter;9/12/2005, Vol. 268 Issue 8, p5 

    Reports that United States-based pharmaceutical firm Glaxosmithkline PLC continued its aggressive pursuit of a top slot in the flu vaccines arena with its bid for Vancouver, British Columbia-based ID Biomedical Corp. Worth of the bid; Benefit of the acquisition to Glaxosmithkline;...

  • Shire agrees on vaccines sale to IDB. Beacham, Will // European Chemical News;4/26/2004, Vol. 80 Issue 2097, p9 

    Reports on the agreement made by Shire Pharmaceuticals to sell its vaccines business to ID Biomedical. Operating loss of the vaccines business in 2003; Details of the agreement; Number of employees affected by the sale.

  • Shire sells non-core vaccines. Tyler, Alan // European Chemical News;4/26/2004, Vol. 80 Issue 2097, p34 

    Deals with an agreement signed by Shire Pharmaceuticals Group of Great Britain to sell its vaccines to Canadian-based biotechnology ID Biomedical. Terms of the deal; Reason of the company for selling its vaccines; Comments from Shire CEO Matthew Emmens on the new strategy of the company.

  • Shire Speculation Sends BioChem Skidding. Cohen, Judy Radler // Mergers & Acquisitions Report;4/30/2001, Vol. 14 Issue 18, p1 

    Reports on the effect of market speculation on the possible acquisition of BioChem Pharma Inc. by Shire Pharmaceuticals Group PLC. Review made by the Canadian Department of Industry on the deal; Estimated cost of the corporate acquisition.

  • Shire Pharma acquires Pharmavene.  // Chemical Business;Mar1997, Vol. 10 Issue 8, p53 

    Looks at the acquisition of Shire Pharmaceuticals of the United States delivery and technology company Pharmavene. Terms of the acquisition payment; Other plans of Shire.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics